ELICIO THERAPEUTICS INC. - COMMON STOCK

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

15 مايو 2024 15:30:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

25 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

05 أبريل 2024 15:30:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

29 مارس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics Announces $6.0 Million Private Placement Financing

18 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

06 مارس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

05 فبراير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

25 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

17 يناير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

16 يناير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

11 يناير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

09 يناير 2024 05:00:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics Announces $7.0 Million Private Placement Financing

22 ديسمبر 2023 08:00:32 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

04 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

09 نوفمبر 2023 15:30:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

03 نوفمبر 2023 15:30:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update

06 يونيو 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting

03 يونيو 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics Reports Inducement Grant to New Chief Financial Officer

02 يونيو 2023 15:30:00 بحسب Nasdaq GlobeNewswire

Elicio Therapeutics Announces Completion of Merger with Angion Biomedica

01 يونيو 2023 15:04:00 بحسب Nasdaq GlobeNewswire